EMEA-000371-PIP02-09

Key facts

Invented name
Revlimid
Active substance
lenalidomide
Therapeutic area
Oncology
Decision number
P/50/2011
PIP number
EMEA-000371-PIP02-09
Pharmaceutical form(s)
  • Capsule
  • hard
Condition(s) / indication(s)
Treatment of diffuse large B-cell lymphoma
Route(s) of administration
Oral use
Contact for public enquiries
Celgene Europe Ltd.

Tel. +41 327298500
E-mail: medinfo.intl@celgene.com

 

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating